Drug major Kopran has received approval from the US patent office for its new chemical entity (NCE) - KNC-6 filed in September 2001.
In a notice to the Bombay Stock Exchange (BSE), KNC-6 is a novel dual action anti-uscerant having significant anti-secretory and cytoprotective properties with quick onset of action.
The company has also filed patent application for KNC-6 in 30 other countries including Japan, Australia, Canada and the European countries.
Lupin to discontinue the sale of share to New bridge Capital by its promoters. In a notice to the Bombay Stock Exchange, the company said that the promoters, Dr D B Gupta & Associates, have decided to discontinue negotiations in respect to the sale of 5037713 equity shares of Rs 10 each constituting 12.55 per cent of equity capital to Newbridge Capital.
Stocks waiting for the news
Watch Out
Our Markets Bureau / Mumbai Oct 14, 2003, 00:00 IST
Content Guide
